alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
PGI 236.213 Special procedures for sealed bidding in construction contracting.       For additive or deductive items—          (1) Use a bid schedule with—          (i) A first or base bid item covering the work generally as specified; and          (ii) A list of priorities that contains one or more additive or deductive bid items that progressively add or omit specified features of the work in a stated order of priority. (Normally, do not mix additive and deductive bid items in the same solicitation.)          (2) Before opening the bids, record in the contract file the amount of funds available for the project.          (3) Determine the low bidder and the items to be awarded in accordance with the procedures in the clause at 252.236-7007, Additive or Deductive Items.    **Parent topic:** PGI 236.2 -SPECIAL ASPECTS OF CONTRACTING FOR CONSTRUCTION
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 41 Engrossed in House (EH)]

                 In the House of Representatives, U.S.,

                                                         March 9, 2005.
Whereas April 6 has a special significance for all Americans, and especially 
        those Americans of Scottish descent, because the Declaration of 
        Arbroath, the Scottish Declaration of Independence, was signed on April 
        6, 1320, and the American Declaration of Independence was modeled in 
        part on that inspirational document;
Whereas this resolution honors the major role that Scottish-Americans played in 
        the founding of the Nation, such as the fact that almost half of the 
        signers of the Declaration of Independence were of Scottish descent, the 
        Governors in 9 of the original 13 States were of Scottish ancestry, and 
        Scottish-Americans successfully helped shape the Nation in its formative 
        years and guide it through its most troubled times;
Whereas this resolution recognizes the monumental achievements and invaluable 
        contributions made by Scottish-Americans that have led to America's 
        preeminence in the fields of science, technology, medicine, government, 
        politics, economics, architecture, literature, media, and visual and 
        performing arts;
Whereas this resolution commends the more than 200 organizations throughout the 
        United States that honor Scottish heritage, tradition, and culture, 
        representing the hundreds of thousands of Americans of Scottish descent, 
        residing in every State, who already have made the observance of Tartan 
        Day on April 6 a success; and
Whereas these numerous individuals, clans, societies, clubs, and fraternal 
        organizations do not let the great contributions of the Scottish people 
        go unnoticed: Now, therefore, be it
    Resolved,  That it is the sense of the House of Representatives that a day 
should be established as ``National Tartan Day'' to recognize the outstanding 
achievements and contributions made by Scottish-Americans to the United States.
            Attest:

                                                                          Clerk.
```
#### PRINCE v. REISER.

(Supreme Court, Appellate Division, First Department.

November 27, 1914.)

Action by Henry Prince against Ely J. Reiser.

No opinion. Motion granted. Order filed. See, also, 163 App. Div. 958, 148 N. Y. Supp. 1139; 149 N. Y. Supp. 1107.
# SUBPART 30.2 – CAS PROGRAM REQUIREMENTS

*(Revised March 29, 2016, through PROCLTR 2016-06)*

**Parent topic:**PART 30 – COST ACCOUNTING STANDARDS ADMINISTRATION

## 30.201-5 Waiver.

(a)(1)(B) Waiver requests for individual procurements shall be submitted to the DLA Acquisition Contract and Pricing Compliance Division for coordination with the DLA Acquisition Director prior to submission to DPC for approval. (e) The DLA Acquisition Compliance, Policy and Pricing Division prepares the annual report on CAS waivers for approval by the Senior Procurement Executive and submits the report to DPC.
#### STORRIER, Respondent, v. MOSIER & SUMMERS, Appellants.

(Supreme Court, Appellate Division, Fourth Department.

January 27, 1915.)

Action by James Storrier against Mosier & Summers.

PER CURIAM.

Judgment and order affirmed, with costs.

ROBSON, J., dissents.
#### BUTLER, Respondent, v. CITY OF NEW YORK, Appellant.

(Supreme Court, Appellate Division, Second Department.

December 11, 1914.)

Action by Michael Butler against the City of New York.

No opinion. Judgment and order unanimously affirmed, with costs.
# PGI 209.106 Preaward surveys.

- PGI 209.106-1 Conditions for preaward surveys. 
- PGI 209.106-2 Requests for preaward surveys. 

**Parent topic:**PGI 209.1 -RESPONSIBLE PROSPECTIVE CONTRACTORS
| (logo) WELLS            FARGO | Commercial Mortgage Servicing

D1086-120, 12th Floor

550 South Tryon Street

Charlotte, NC 28202

1-800-326-1334 |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|

 

 

ANNUAL STATEMENT OF COMPLIANCE

 

 

                Reference is hereby made to that certain Pooling and Servicing Agreement dated as of March 1, 2013, by and among WELLS FARGO COMMERCIAL MORTGAGE SECURITIES, INC., as Depositor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as General Master Servicer, RIALTO CAPITAL ADVISORS, LLC, as General Special Servicer, NCB, FSB, as NCB Master Servicer, NCB, FSB, as Co-op Special Servicer, PENTALPHA SURVEILLANCE LLC, as Trust Advisor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Certificate Administrator,  as  Tax  Administrator  and  as  Custodian, and  U.S. BANK  NATIONAL ASSOCIATION, as Trustee, with respect to Commercial Mortgage Pass-Through Certificates WFRBS 2013-C12 (the "Agreement"). Capitalized terms used herein not otherwise defined shall have the meanings assigned in the Agreement.

 

Pursuant to Section 11.12 of this Agreement, I, Daniel Bober, Executive Vice President of Commercial Mortgage Services do hereby certify that:

 

1.         A review of the activities of the Servicer during the period from January 1, 2014 through December 31, 2014 (the “Reporting Period”), and of its performance per the Agreement during such period has been made under my supervision, and

 

2.         To the best of my knowledge, based on such review, the Servicer, has fulfilled all of its obligations under this Agreement in all material respects throughout the Reporting Period.

 

 

IN WITNESS WHEREOF, the undersigned has executed this Certificate as of the 6th day of March 2015.

 

 

 

/s/  Daniel Bober            

Daniel Bober

Executive Vice President

Wells Fargo Bank

 

 

 

 

 
| Wells Fargo Bank, N.A. | (logo) Together we’ll go far |
|------------------------|------------------------------------|
§ 455.21 Submission and approval of State Plans and State Plan amendments. ( a ) Proposed State Plans or Plan amendments necessitated by a change in regulations shall be submitted to DOE within 90 days of the effective date of this subpart or any amended regulations. Upon request by a State, and for good cause shown, DOE may grant an extension of time.
( b ) The Support Office Director shall, within 60 days of receipt of a proposed State Plan, review each plan and, if it is reasonable and found to conform to the requirements of this part, approve the State Plan. If the Support Office Director does not disapprove a State Plan within the 60-day period, the State Plan will be deemed to have been approved.
( c ) If the Support Office Director determines that a proposed State Plan fails to comply with the requirements of this part or is not reasonable, DOE shall return the plan to the State with a statement setting forth the reasons for disapproval.
( d ) Except for State Plan amendments covered by paragraph (a) of this section, if a State wishes to deviate from its approved State Plan, the State must submit and obtain DOE approval of the State Plan amendment.
( e ) The Support Office Director shall, within 60 days or less of receipt of a proposed State Plan amendment review each amendment and, if it is found to conform to the requirements of this part, approve the amendment. If the Support Office Director determines that a proposed State Plan amendment fails to comply with the requirements of this part, or is not reasonable, DOE shall return the amendment to the State with a statement setting forth the reasons for disapproval.
**MEMORANDUM**

DATE: 11/14/14 TO: Clean Power Plan for Existing Power Plants; Docket I d: OAR

–2013
- 0602 FROM: Ray

Saracino , EPA Region 9 SUBJECT: November 14, 2014 M eeting with Northern Arizona University (NAU) Regarding

Proposed Clean Power Plan for Existing Power Plants
**SUMMARY** A meeting was held between EPA and the attendees listed below on November 14, 2014 to discuss the proposed Clean Power Plan for Existing Power Plants
. The Clean Power Plan for Existing Power Plants was proposed on June 2 , 2014 and published in the Federal Register on June 18, 2014. **ATTENDEES External Stakeholders**  Jeff Downard, NAU Fletcher Wilkinson, NAU Jeff Busan, NAU Steve Burr, ADEQ Tai Wallace, ADEQ **EPA** Ray Saracino **Attachment** Filename: 111(d) Docket Memo Attachment_NAU Questions for EPA and ADEQ
#### § 501.65 Publication of notice of availability of draft EIS.

A Notice of Availability of any draft EIS will be published in the Federal Register and comments thereon will also be solicited. Interested persons may request a hearing on any draft EIS. Such hearing must be requested within thirty (30) days of publication of the Notice of Availability of the draft EIS.

[54 FR 52893, Dec. 22, 1989]
EXHIBIT
        32.1
 
 CERTIFICATION
        PURSUANT TO
 SECTION
        906 OF THE SARBANES-OXLEY ACT OF 2002
 OF
        QUARTERLY REPORT ON FORM 10 - QSB
 OF
        SIONIX
        CORPORATION
 FOR
        THE
        PERIOD ENDED JUNE 30, 2007
 
 The
        undersigned is the Chief Executive Officer of Sionix Corporation (the
        "Company"). This certification is made pursuant to Section 906 of
        the
 Sarbanes-Oxley
        Act of 2002. This certification accompanies the Quarterly Report on Form
        10-QSB of the Company for the period ended June 30, 2007 (the
        "Report").
 
 I,
        James
        J. Houtz, certify that:
  (i)   the
            Report fully complies with the requirements of section 13(a)
            or
            15(d) of the Securities Exchange Act of 1934, and
 
 (ii)
                  the
                      information contained in the Report fairly presents, inall
                      material respects, the financial condition and results ofoperations
                      of the Company.
  This
        certification is executed as of August 14, 2007
  /s/ James J. HoutzJames
                J. Houtz, Chief Executive
                Officer
[Federal Register Volume 75, Number 244 (Tuesday, December 21, 2010)]
[Notices]
[Page 80061]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-31986]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0626]


Abbott Laboratories, Inc.; Withdrawal of Approval of a New Drug 
Application for MERIDIA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval 
of a new drug application (NDA) for MERIDIA (sibutramine hydrochloride 
(HCl)) oral capsules held by Abbott Laboratories, Inc. (Abbott), 100 
Abbott Park Rd., Abbott Park, IL 60064. Abbott has voluntarily 
requested that approval of this application be withdrawn, thereby 
waiving its opportunity for a hearing.

DATES: Effective December 21, 2010.

FOR FURTHER INFORMATION CONTACT: Nicole Mueller, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, rm. 6312, Silver Spring, MD 20993-0002, 301-
796-3601.

SUPPLEMENTARY INFORMATION: On October 7, 2010, FDA requested that 
Abbott voluntarily withdraw MERIDIA (sibutramine HCl) oral capsules 
from the market, based on FDA's recent analysis of clinical trial data 
from the Sibutramine Cardiovascular Outcomes Trial (SCOUT) that 
indicated that MERIDIA poses an increased risk of heart attack and 
stroke. In a letter dated October 12, 2010, Abbott requested that FDA 
withdraw approval of NDA 20-632 for MERIDIA (sibutramine HCl) oral 
capsules under Sec.  314.150(d) (21 CFR 314.150(d)). In that letter, 
Abbott also waived its opportunity for a hearing, provided under Sec.  
314.150(a). In FDA's acknowledgment letter of November 1, 2010, the 
agency stated that based on the review of the SCOUT data and the 
assessment of the September 15, 2010, meeting of FDA's Endocrinologic 
and Metabolic Drugs Advisory Committee at which the SCOUT data were 
reviewed, we find the benefits of MERIDIA (sibutramine HCl) oral 
capsules, indicated for the management of obesity, including weight 
loss and maintenance of weight loss, no longer outweigh the risks in 
any identifiable patient population. FDA also acknowledged that Abbott 
waived its opportunity for a hearing.
    Therefore, under section 505(e) of the Federal Food, Drug, and 
Cosmetic Act (FD&C Act) (21 U.S.C. 355(e)), Sec.  314.150(d), and under 
authority delegated by the Commissioner of Food and Drugs to the 
Director, Center for Drug Evaluation and Research, approval of NDA 20-
632, and all amendments and supplements thereto, is withdrawn (see 
DATES). Distribution of this product in interstate commerce without an 
approved application is illegal and subject to regulatory action (see 
sections 505(a) and 301(d) of the FD&C Act (21 U.S.C. 355(a) and 
331(d)).

    Dated: December 6, 2010.
Janet Woodcock,
Director, Center for Drug Evaluation and Research.
[FR Doc. 2010-31986 Filed 12-20-10; 8:45 am]
BILLING CODE 4160-01-P
# EUR-Lex - 31975L0379 - EN

Avis juridique important

*|*

# 31975L0379

**Council Directive 75/379/EEC of 24 June 1975 amending Directives No 64/432/EEC, No 64/433/EEC, No 71/118/EEC, No 72/461/EEC and No 72/462/EEC as regards the validity of the procedures of the Standing Veterinary Committee **

*
Official Journal L 172 , 03/07/1975 P. 0017 - 0017 Finnish special edition: Chapter 3 Volume 6 P. 0090 Greek special edition: Chapter 03 Volume 13 P. 0032 Swedish special edition: Chapter 3 Volume 6 P. 0090 *

COUNCIL DIRECTIVE of 24 June 1975 amending Directives No 64/432/EEC, No 64/433/EEC, No 71/118/EEC, No 72/461/EEC and No 72/462/EEC as regards the validity of the procedures of the Standing Veterinary Committee (75/379/EEC)

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community, and in particular Articles 43 and 100 thereof;

Having regard to the proposal from the Commission;

Having regard to the Opinion of the European Parliament (1);

Whereas the Standing Veterinary Committee, established by Decision No 68/361/EEC (2), expresses its Opinion in accordance with procedures, the validity of which was limited to a period of 30 months from the date on which a request for an Opinion is first referred to the said Committee;

Whereas a matter was first referred to the Committee on 22 December 1972 ; whereas the period which has elapsed is insufficient to enable a final decision to be reached, and whereas the validity of the aforementioned procedures should only be extended temporarily;

HAS ADOPTED THIS DIRECTIVE:

Article 1

In the following Articles, the term "30 months" is replaced by "102 months": - Article 14 of Council Directive No 64/432/EEC (3) of 26 June 1964 on animal health problems affecting intra-Community trade in bovine animals and swine, as last amended by Council Directive No 74/387/EEC (4);

- Article 9b of Council Directive No 64/433/EEC (5) of 26 June 1964 on health problems affecting intra-Community trade in fresh meat, as last amended by Directive No 74/387/EEC;

- Article 13 of Council Directive No 71/118/EEC (6) of 15 February 1971 on health problems affecting trade in fresh poultry-meat, as last amended by Directive No 74/387/EEC;

- Article 10 of Council Directive No 72/461/EEC (7) of 12 December 1972 on health problems affecting intra-Community trade in fresh meat, as last amended by Directive No 74/387/EEC;

- Article 31 of Council Directive No 72/462/EEC (8) of 12 December 1972 on health and veterinary inspection problems upon importation of bovine animals and swine and fresh meat from third countries, as last amended by Directive No 74/387/EEC.

Article 2

This Decision is addressed to the Member States.

Done at Luxembourg, 24 June 1975.

For the Council

The President

M.A. CLINTON (1)OJ No C 111, 20.5.1975, p. 26. (2)OJ No L 255, 18.10.1968, p. 23. (3)OJ No 121, 29.7.1964, p. 1977/64. (4)OJ No L 202, 24.7.1974, p. 36. (5)OJ No 121, 29.7.1964, p. 2012/64. (6)OJ No L 55, 8.3.1971, p. 23. (7)OJ No L 302, 31.12.1972, p. 24. (8)OJ No L 302, 31.12.1972, p. 28.
Exhibit 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18,
United States Code), each of the undersigned officers of FNB United Corp., a North Carolina corporation (the Corporation), does hereby certify that:

The Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 (the Form 10-Q) of the Corporation fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all materials respects, the financial condition and results of operations of the Corporation.



|                      |  |  |  |  |  |                        
|--------------------- |  |  |  |  |  | -----------------------
|Date: August 10, 2010 |  |  |  |  |  | /s/R. LARRY CAMPBELL   
|                      |  |  |  |  |  | R. Larry Campbell      
|                      |  |  |  |  |  | Chief Executive Officer



|                      |  |  |  |  |  |                        
|--------------------- |  |  |  |  |  | -----------------------
|Date: August 10, 2010 |  |  |  |  |  | /s/MARK A. SEVERSON    
|                      |  |  |  |  |  | Mark A. Severson       
|                      |  |  |  |  |  | Chief Financial Officer

The foregoing
certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of the Form 10-Q or as a
separate disclosure document.
-,-...

•

FEDERAL REQUIRD1ENT

RCRA REVISION C~EC~LIST 3

Interiln Status Staneards ~pplicability

48 FR 52718-20

November 22, 1983

RCRA CITE STATE AL7HORITY IF DIFFERE~7 FROM FEDERAL

STATl,7E REGULATION REQUIREMENT, EXPLAIN

PART 265 - INTERIM STA.~rAR.CS FOR a-,lNERS AND OPERATORS OF TSDF'.S

SlJBP.;RT A - GrnG..b..L

PURPOSE, SCOPE AND APPLICABILITY

•

•

persons to whan reg s

apply 265.l.(b) 73-303-400( 1\ & ~2)

'.Jo\,t?"\ber 22, 1983 - ?3~e 1 of 1
Exhibit 11

                    CTC COMMUNICATIONS CORP.
       STATEMENTS REGARDING COMPUTATION OF PER SHARE EARNINGS
              (IN THOUSANDS EXCEPT FOR PER SHARE DATA)

<TABLE>
<CAPTION>
                                                  Three Months Ended              Nine Months Ended
                                              December 31,   December 31,    December 31,   December 31,
                                                1996           1995            1996            1995
                                             -------------  -------------   -------------  -------------
PRIMARY
<S>                                          <C>            <C>              <C>            <C>
Average shares outstanding                       1,098          1,191            1,238          1,088

Net effect of stock options, if dilutive,
  based on the treasury stock method
  using the average market price                 9,608          9,482            9,598          9,400
                                             ----------     ----------       ----------     ----------
                                 Total          10,706         10,673           10,836         10,488

Net income                                   $   1,159      $   1,175        $   3,402      $   2,813
                                             ----------     ----------       ----------     ----------
Net income per share                         $    0.11      $    0.11        $    0.31      $    0.27
                                             ----------     ----------       ----------     ----------


FULLY DILUTED

Average shares outstanding                       1,098          1,191            1,254          1,130

Net effect of stock options, if dilutive,
  based on the treasury stock method
  using the period-end market price              9,608          9,482            9,598          9,400
                                             ----------     ----------       ----------     ----------
                                 Total          10,706         10,673           10,852         10,530

Net income                                   $   1,159      $   1,175        $   3,402      $   2,813
                                             ----------     ----------       ----------     ----------
Net income per share                         $    0.11      $    0.11        $    0.31      $    0.27
                                             ----------     ----------       ----------     ----------
</TABLE>